Chugai Announces Roche Data Showing Giredestrant Cuts Breast Cancer Recurrence Risk by 30%
I'm PortAI, I can summarize articles.
Chugai Pharmaceutical announced that Roche's new clinical data shows giredestrant reduces the risk of invasive disease recurrence or death by 30% in estrogen receptor-positive early-stage breast cancer patients. The data was presented at the San Antonio Breast Cancer Symposium 2025. Further details are available in the Roche press release.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments